Analgesic effect of oral paracetamol 1000 mg/ibuprofen 400 mg, paracetamol 1000 mg/codeine 60 mg, paracetamol 1000 mg/ibuprofen 400 mg/codeine 60 mg, or placebo on acute postoperative pain: a single-dose, randomized, and double-blind study
Purpose Combining analgesics with different mechanisms of action may increase the analgesic efficacy. The multidimensional pharmacodynamic profiles of ibuprofen 400 mg/paracetamol 1000 mg, ibuprofen 400 mg/paracetamol 1000 mg/codeine 60 mg, and paracetamol 1000 mg/codeine 60 mg and placebo were compared. Methods A randomized, double-blind, placebo-controlled, parallel-group, single-centre, outpatient, and single-dose study used 200 patients of both sexes and homogenous ethnicity after third molar surgery (mean age 24 years, range 19–30 years). Primary outcome was sum pain intensity over 6 h (SPI). Secondary outcomes were time to analgesic onset, duration of analgesia, time to rescue drug intake, number of patients taking rescue drug, sum pain intensity difference (SPID), maximum pain intensity difference, time to maximum pain intensity difference, number needed to treat, prevent remedication and harm values, adverse effects, and patient-reported outcome measure (PROM). Results Analgesia following ibuprofen and paracetamol combination with or without codeine was comparable. Both were better than paracetamol combined with codeine. Secondary variables supported this finding. Post hoc analysis of SPI and SPID revealed a sex/drug interaction trend in the codeine-containing groups where females experienced less analgesia. PROM showed a significant sex/drug interaction in the paracetamol and codeine group, but not in the other codeine-containing group. Especially females reported known and mild side effects in the codeine-containing groups. Conclusion Codeine added to ibuprofen/paracetamol does not seem to add analgesia in a sex-mixed study population. Sex may be a confounding factor when testing weak opioid analgesics such as codeine. PROM seems to be more sensitive than traditional outcome measures. Trial registration ClinicalTrials.gov June 2009 NCT00921700..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
European journal of clinical pharmacology - 79(2023), 8 vom: 22. Juni, Seite 1131-1141 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lyngstad, Gaute [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
Codeine |
| Anmerkungen: |
© The Author(s) 2023. corrected publication 2024 |
|---|
| doi: |
10.1007/s00228-023-03525-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR052327299 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR052327299 | ||
| 003 | DE-627 | ||
| 005 | 20240424064656.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230722s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00228-023-03525-0 |2 doi | |
| 035 | |a (DE-627)SPR052327299 | ||
| 035 | |a (SPR)s00228-023-03525-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Lyngstad, Gaute |e verfasserin |0 (orcid)0000-0003-3169-3287 |4 aut | |
| 245 | 1 | 0 | |a Analgesic effect of oral paracetamol 1000 mg/ibuprofen 400 mg, paracetamol 1000 mg/codeine 60 mg, paracetamol 1000 mg/ibuprofen 400 mg/codeine 60 mg, or placebo on acute postoperative pain: a single-dose, randomized, and double-blind study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023. corrected publication 2024 | ||
| 520 | |a Purpose Combining analgesics with different mechanisms of action may increase the analgesic efficacy. The multidimensional pharmacodynamic profiles of ibuprofen 400 mg/paracetamol 1000 mg, ibuprofen 400 mg/paracetamol 1000 mg/codeine 60 mg, and paracetamol 1000 mg/codeine 60 mg and placebo were compared. Methods A randomized, double-blind, placebo-controlled, parallel-group, single-centre, outpatient, and single-dose study used 200 patients of both sexes and homogenous ethnicity after third molar surgery (mean age 24 years, range 19–30 years). Primary outcome was sum pain intensity over 6 h (SPI). Secondary outcomes were time to analgesic onset, duration of analgesia, time to rescue drug intake, number of patients taking rescue drug, sum pain intensity difference (SPID), maximum pain intensity difference, time to maximum pain intensity difference, number needed to treat, prevent remedication and harm values, adverse effects, and patient-reported outcome measure (PROM). Results Analgesia following ibuprofen and paracetamol combination with or without codeine was comparable. Both were better than paracetamol combined with codeine. Secondary variables supported this finding. Post hoc analysis of SPI and SPID revealed a sex/drug interaction trend in the codeine-containing groups where females experienced less analgesia. PROM showed a significant sex/drug interaction in the paracetamol and codeine group, but not in the other codeine-containing group. Especially females reported known and mild side effects in the codeine-containing groups. Conclusion Codeine added to ibuprofen/paracetamol does not seem to add analgesia in a sex-mixed study population. Sex may be a confounding factor when testing weak opioid analgesics such as codeine. PROM seems to be more sensitive than traditional outcome measures. Trial registration ClinicalTrials.gov June 2009 NCT00921700. | ||
| 650 | 4 | |a Paracetamol |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ibuprofen |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Codeine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Combination |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Postoperative pain |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Third molar |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Skjelbred, Per |e verfasserin |0 (orcid)0000-0002-5193-7827 |4 aut | |
| 700 | 1 | |a Swanson, David Michael |e verfasserin |0 (orcid)0000-0003-3174-1656 |4 aut | |
| 700 | 1 | |a Skoglund, Lasse Ansgar |e verfasserin |0 (orcid)0000-0003-1863-2738 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical pharmacology |d Springer Berlin Heidelberg, 1968 |g 79(2023), 8 vom: 22. Juni, Seite 1131-1141 |w (DE-627)SPR002560860 |w (DE-600)1459058-X |x 1432-1041 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2023 |g number:8 |g day:22 |g month:06 |g pages:1131-1141 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00228-023-03525-0 |m X:SPRINGER |x Resolving-System |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |q VZ |
| 936 | b | k | |a 44.38 |q VZ |
| 951 | |a AR | ||
| 952 | |d 79 |j 2023 |e 8 |b 22 |c 06 |h 1131-1141 | ||